HNF Awards the inaugural HNF Clinical Translation Fellowship

by | Aug 16, 2024 | 2 comments

HNF Awards the inaugural HNF Clinical Translation Fellowship in the amount of $170,000 to Kayla Cornett, PhD

We are thrilled to announce the establishment of the HNF Clinical Translation Fellowship, awarded to Kayla Cornett, PhD, a distinguished postdoctoral research fellow at the University of Sydney and the Children’s Hospital at Westmead. Dr. Cornett is recognized for her expertise in clinical outcome measurement for pediatric neuromuscular diseases, particularly Charcot-Marie-Tooth (CMT).

About Dr. Kayla Cornett

Dr. Cornett’s work is at the forefront of pediatric neuromuscular research. As an early-career researcher, she has already authored over 45 publications, including a seminal report in the Annals of Neurology on the natural history of CMT during childhood. Her collaborative efforts with leading researchers worldwide have significantly advanced the reliable and sensitive assessment of function in children with neuromuscular diseases.

Fellowship Overview

As the landscape of drug development for CMT rapidly evolves, with therapies like small molecules, RNA-targeted therapies, and gene replacement advancing toward clinical application, the need for tailored clinical trial outcome measures has never been more critical. This fellowship aims to address this need by developing new measurement tools, including remote tools for tracking disease progress, training clinicians, assessing patient natural history through global expansion of the GRIN patient registry, and disseminating valuable information to the global CMT community.

Impact on the CMT Community

This fellowship will play a pivotal role in advancing clinical research and care for CMT patients. The work undertaken by Dr. Cornett will not only improve the precision of clinical trials for both adults and children, but also provide more accurate and meaningful assessments of patient outcomes. The expansion of GRIN globally will enable more comprehensive data collection, ultimately leading to better-informed treatments and therapies for those affected by CMT.

We are excited to support Dr. Cornett’s groundbreaking work and look forward to the significant contributions she will make to the field of CMT research.

Stay tuned for updates on her progress and the impact of this fellowship on the global CMT community.

 

Learn more on this topic

Related Blog Posts

Global Registry For Inherited Neuropathies: Your Questions Answered

Global Registry For Inherited Neuropathies: Your Questions Answered

Why are we asking you to join our registry? It’s simple. Without you, researchers won’t have the essential patient information to develop the drugs, gene therapy, and clinical trials for Charcot-Marie-Tooth and other inherited neuropathies.
This is why the Hereditary Neuropathy Foundation (HNF) created the Global Registry for Inherited Neuropathies (GRIN). The registry collects the historical, clinical, and genetic information on patients diagnosed with the various forms of inherited neuropathies to help advance therapy development for these debilitating disorders. We understand there may be some hesitation joining our registry. To help mitigate any concerns, we’ve have the answers to your most common questions.

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Scientific Advisory Board Meeting

Scientific Advisory Board Meeting

On the 7th of November we convened our scientific advisory board meeting at the HNF offices in NY. We have written a detailed review that has been published and captures all of the discussion and make this freely available to the scientific community.

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

PARIS, December 18th, 2014 – Pharnext SAS today announced the proof of concept of its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases. Indeed, Pharnext’s lead pleodrug, PXT-3003, has shown positive results both in preclinical and Phase 2 clinical studies published today in the Orphanet Journal of Rare Diseases.

Join the conversation

Leave a Comment

2 Comments

  1. Laure Ebel

    Where can I get information specifically regarding HNPP ?

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news